Abstract
Adverse drug reactions (ADRs) to first-line anti-tuberculosis drugs are common and may cause associated morbidity and even mortality if not recognized early.1–3 The overall prevalence of ADRs with first-line anti-tuberculosis drugs is estimated to vary from 8.0% to 85%. They are observed more commonly in the intensive phase and do not differ with intermittent or daily intake of anti-tuberculosis drugs. The occurrence of ADRs may be influenced by multiple factors and may range from mild gastrointestinal disturbances to serious hepatotoxicity, peripheral neuropathy, cutaneous adverse effects, etc. Early recognition and appropriate management of these adverse effects might determine adherence and treatment success.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
